Streetwise Reports' Article Archives — October 2024 back to current month (15)
AI Healthcare Co. With 'Bright' Outlook Closes Placement (10/31/2024)
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on.
Biotech Shares Positive Phase I Data for Alzheimer's Treatment (10/31/2024)
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.
Mass. Biotech Shares Strong Q3 Results (10/29/2024)
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note.
Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments (10/28/2024)
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy.
Boston Biotech Announces Novartis Collaboration (10/28/2024)
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note.
H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates (10/23/2024)
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Silver Break Out Confirmed (10/22/2024)
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell.
NY Biopharma Shares Promising Clinical Data (10/18/2024)
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note.
Is This AI Healthcare Stock Worth Being Overweight On? (10/09/2024)
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. (10/09/2024)
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.
Mass. Biotech Receives FDA Approval (10/07/2024)
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note.
AI Integration Enhances Capabilities of Defense Drones for Key Military Operations (10/04/2024)
Red Cat Holdings Inc. (RCAT:NASDAQ) and Palladyne AI Corp. have announced a new partnership to integrate Palladyne AIs artificial intelligence (AI) platform, Palladyne Pilot, into Red Cats Teal drones. Read how this changes the capabilities for smaller scale drone platforms.
CT Biotech Ready for Clinical Milestones (10/04/2024)
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note.
Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial (10/03/2024)
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton.
New Jersey Biotech Reports Positive Survival Data (10/02/2024)
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.
More Archives
2024Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
